Vaccine Info

Adacel Vaccine 2023

Authored by
Staff
Last reviewed
January 11, 2023
Fact checked by
Robert Carlson, MD
Share

Adacel® Vaccine Description 2023

Sanofi Pasteur Limited Adacel® vaccine (Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine, Adsorbed) contains noninfectious tetanus, diphtheria, and pertussis proteins, aluminum phosphate, 2-phenoxyethanol, and residual amounts of formaldehyde and glutaraldehyde. Adacel vaccine does not contain preservatives.

Adacel is a vaccine indicated for active booster immunization against tetanus, diphtheria, and pertussis. Adacel is U.S. Food and Drug Administration (FDA) approved (STN: BL 125111/904 ) for use in persons 10 through 64 years of age and immunization during the third trimester of pregnancy to prevent pertussis in infants younger than two months of age.

Adacel Vaccine Indication

Adacel (Tdap) is indicated for active booster immunization to prevent tetanus, diphtheria, and pertussis in people at least ten through 64.

Adacel given during the third trimester of pregnancy, helps the pregnant woman create antibodies against the bacteria that cause whooping cough (pertussis) that are passed to her baby before birth. These antibodies help protect the baby against whooping cough during the first few months of life.

Adacel Vaccine Dosage

The Adacel vaccine is administered as an intramuscular injection into the muscle of the upper arm and approved as a single dose in individuals ten through age. 64 Therefore, most people in this age group require only one Tdap shot for protection against these diseases. Adacel is available in a syringe made without natural rubber latex, which may help reduce risk to patients with an allergy.

Adacel Vaccine News

January 10, 2023 - The U.S. FDA announced Adacel was approved for immunization during the third trimester of pregnancy to prevent pertussis in infants younger than two months.

January 15, 2019 - 1st Tdap Vaccine Approved for a 2nd Dose.

January 11, 2019 - The U.S. Food and Drug Administration has approved the expanded use of Adacel® (Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine Adsorbed) to include repeat vaccination to help protect against tetanus, diphtheria, and pertussis. It is now the first and only Tdap vaccine in the U.S. approved for a repeat dose in people 10 through 64 years.

Adacel Vaccine Clinical Trials

Adacel has been involved in over 19 clinical studies.

Clinical Trials

No clinical trials found